S&P 500   3,312.02 (-0.29%)
DOW   29,056.66 (-0.44%)
QQQ   223.74 (-0.06%)
AAPL   317.95 (+0.08%)
FB   219.91 (-0.64%)
MSFT   166.06 (+0.22%)
AMZN   1,879.20 (-0.44%)
CGC   24.34 (+0.91%)
NVDA   251.60 (+0.62%)
BABA   217.71 (-2.10%)
MU   59.41 (+0.41%)
GE   11.72 (+3.08%)
TSLA   564.49 (-0.89%)
AMD   51.22 (-0.41%)
F   9.04 (-1.31%)
NFLX   343.62 (+5.40%)
PRI   123.50 (-2.49%)
DIS   141.64 (-1.65%)
GILD   63.15 (-0.44%)
S&P 500   3,312.02 (-0.29%)
DOW   29,056.66 (-0.44%)
QQQ   223.74 (-0.06%)
AAPL   317.95 (+0.08%)
FB   219.91 (-0.64%)
MSFT   166.06 (+0.22%)
AMZN   1,879.20 (-0.44%)
CGC   24.34 (+0.91%)
NVDA   251.60 (+0.62%)
BABA   217.71 (-2.10%)
MU   59.41 (+0.41%)
GE   11.72 (+3.08%)
TSLA   564.49 (-0.89%)
AMD   51.22 (-0.41%)
F   9.04 (-1.31%)
NFLX   343.62 (+5.40%)
PRI   123.50 (-2.49%)
DIS   141.64 (-1.65%)
GILD   63.15 (-0.44%)
S&P 500   3,312.02 (-0.29%)
DOW   29,056.66 (-0.44%)
QQQ   223.74 (-0.06%)
AAPL   317.95 (+0.08%)
FB   219.91 (-0.64%)
MSFT   166.06 (+0.22%)
AMZN   1,879.20 (-0.44%)
CGC   24.34 (+0.91%)
NVDA   251.60 (+0.62%)
BABA   217.71 (-2.10%)
MU   59.41 (+0.41%)
GE   11.72 (+3.08%)
TSLA   564.49 (-0.89%)
AMD   51.22 (-0.41%)
F   9.04 (-1.31%)
NFLX   343.62 (+5.40%)
PRI   123.50 (-2.49%)
DIS   141.64 (-1.65%)
GILD   63.15 (-0.44%)
S&P 500   3,312.02 (-0.29%)
DOW   29,056.66 (-0.44%)
QQQ   223.74 (-0.06%)
AAPL   317.95 (+0.08%)
FB   219.91 (-0.64%)
MSFT   166.06 (+0.22%)
AMZN   1,879.20 (-0.44%)
CGC   24.34 (+0.91%)
NVDA   251.60 (+0.62%)
BABA   217.71 (-2.10%)
MU   59.41 (+0.41%)
GE   11.72 (+3.08%)
TSLA   564.49 (-0.89%)
AMD   51.22 (-0.41%)
F   9.04 (-1.31%)
NFLX   343.62 (+5.40%)
PRI   123.50 (-2.49%)
DIS   141.64 (-1.65%)
GILD   63.15 (-0.44%)
Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

$116.82
+1.20 (+1.04 %)
(As of 01/23/2020 01:01 PM ET)
Today's Range
$112.73
Now: $116.83
$117.84
50-Day Range
$114.65
MA: $118.07
$124.28
52-Week Range
$65.81
Now: $116.83
$125.72
Volume217,364 shs
Average Volume477,764 shs
Market Capitalization$13.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.91 million
Book Value$12.87 per share

Profitability

Net Income$-761,490,000.00
Net Margins-485.73%

Miscellaneous

Employees1,065
Market Cap$13.02 billion
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($2.17) by $0.25. The biopharmaceutical company earned $70.06 million during the quarter, compared to analysts' expectations of $57.14 million. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. The firm's quarterly revenue was up 3284.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.56) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

17 brokers have issued 12-month price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $190.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $121.59 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.

What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alnylam incurred narrower-than-expected loss and beat revenue estimates in the third quarter of 2019. Onpattro continued to gain traction. The FDA set an action date of Feb 20, 2020. It showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy and a potential label expansion should boost sales.The company’s efforts to develop its pipeline (inclisiran and lumasiran) are impressive. The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, heavy dependence on Onpattro for growth is a concern. Moreover, the company heavily relies on its partnerships for supporting operations.Shares have outperformed the industry." (11/19/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

Media coverage about ALNY stock has been trending extremely negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Alnylam Pharmaceuticals.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 4,420,000 shares, a decline of 10.5% from the December 15th total of 4,940,000 shares. Based on an average trading volume of 694,700 shares, the short-interest ratio is currently 6.4 days. Approximately 4.0% of the company's stock are sold short. View Alnylam Pharmaceuticals' Current Options Chain.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), NXP Semiconductors (NXPI), Gilead Sciences (GILD), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
  • Mr. Barry E. Greene, Pres (Age 56)
  • Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
  • Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.14%), Coronation Fund Managers Ltd. (0.09%), Rhenman & Partners Asset Management AB (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), DNB Asset Management AS (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Coronation Fund Managers Ltd., Nisa Investment Advisors LLC, Rhenman & Partners Asset Management AB, Zeke Capital Advisors LLC, IFM Investors Pty Ltd and Gateway Investment Advisers LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Barry E Greene, John Maraganore, Marsha Fanucci, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Polianta Ltd, Zurcher Kantonalbank Zurich Cantonalbank , Tocqueville Asset Management L.P., IBM Retirement Fund, DNB Asset Management AS, Exchange Traded Concepts LLC and Huntington National Bank. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $116.83.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $13.02 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  940 (Vote Outperform)
Underperform Votes:  464 (Vote Underperform)
Total Votes:  1,404
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel